Wall Street has fixated on the obesity pill as a way for the company to revive itself, pressing Bourla for any hints that his company might one day compete in the era-defining market for obesity treatments
The mechanism is plausible (direct delivery should theoretically accelerate results), but the evidence base is not comparable to what exists for topical application
So Lillys obesity strategy looks less like a single-product story and more like a portfolio strategy: multiple mechanisms, multiple formats, and multiple clinical questions
There are also no FDA-approved generic versions of these products
Then in 2019, a meta-analysis study tried to clarify the OS marker profile in ALS patients: the authors demonstrated that 8-OHdG and MDA were significantly increased in the peripheral blood of ALS patients when compared with control subjects, while GSH levels were significantly reduced
One of those other things, it turns out, is erectile performance